Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination .
CONCLUSION: When comparing the AUClast and Cmax of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence.
.
PMID: 30574864 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
More News: Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Electrocardiogram | Endocrinology | Fortamet | Laboratory Medicine | Metformin | Study